Clinical Trial Search

Primary: The Nisonger Child Behavior Rating Form- Typical Intelligence Quotient (NCBRF-TIQ) Conduct Problem Subscale Score — 20.4; 25.7; 26.0; 26.0 score on a scale

Primary: Center for Epidemiologic Studies-Depression (CES-D) Scale Mean Total Score — 12.96; 18.02; 11.53; 9.43 Units on a scale

Primary: Proportion of Safety Events — 1 Participants

Primary: Number of Participants With Adverse Events (AEs) in Part 1. — 7; 9; 9 Participants

Primary: Percentage of Participants With Pathologic Complete Response (pCR) as Determined by Local Pathologic Review — 16.7; 50.0 percentage of participants

Primary: Safety, Tolerability and Dose Limiting Toxicity (DLT) of Ibrutinib in Combination With Obinutuzumab — 32 Participants

Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 24; 28; 9; 8 Participants

Primary: Proportion of Subjects Who Achieved Durable Phlebotomy-free Complete Hematological Response (CHR) at Month 12 — 8 Participants

Primary: Change in Best Corrected Visual Acuity by ETDRS Visual Scale Testing — 2.7 Change in letters (BCVA)

Primary: Change in Best Corrected Visual Acuity by Early Treatment Diabetic Retinopathy Study Chart Visual Scale Testing — 4.5 Change in letters (BCVA)

Primary: Change in Best Corrected Visual Acuity — 6.0; 4.6 Change in letters (BCVA)

Primary: Percentage of Participants With 2-Year Progression-Free Survival (PFS) — 38; 61 Percentage of participants

Primary: Ocular Itching as Measured by Self-reported Numerical Scales — -0.228; 0.010; -0.424; -0.035 score on a scale

Primary: Number of Participants With Unacceptable Toxicity. — 0 Participants

Primary: Safety (Adverse Events) — 8; 6; 0; 0 Participants